Why the study?
Dilated and hypertrophic cardiomyopathies have a genetic origin in 30 to 50% of cases, making evaluation of these etiologies a crucial tool in patient management.
Population
Patients with cardiomyopathies
Design
Systematic_review
Authors
Loading...
Genetic evaluation aids cardiomyopathy management; leaves open precise mutation-phenotype links for targeted therapies.
Recognizing the main mutations associated with cardiomyopathies enables a more individualized medicine approach with early interventions, risk stratification, and family screening.
Hama et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: